Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Familial haemophagocytic lymphohistiocytosis (FHL) is a rare autosomal recessive disorder of immune dysregulation associated with uncontrolled T cell and macrophage activation and hypercytokinaemia. The incidence of FHL is 0·12/100·000 children born per year, with a male to female ratio of 1:1. The disease is classified into six different types based on genetic linkage analysis and chromosomal localization; five specific genetic defects have been identified, which account for approximately 90% of all patients. Type 1 is due to an as yet unidentified gene defect located on chromosome nine. Type 2 is caused by mutations in the perforin (PRF1) gene, type 3 by mutations in the Munc-13–4 (UNC13D) gene, type 4 by mutations in the syntaxin 11 (STX11) gene and the recently described type 5 due to mutations in the gene encoding syntaxin binding protein 2 (STXBP-2). The incidence of the five types varies in different ethnic groups. The most common presenting features are pyrexia of unknown origin, pronounced hepatosplenomegaly and cytopenias. Neurological features tend to present later and are associated with poor prognosis. Absent or decreased lymphocyte cytotoxicity is the cellular hallmark of FHL. Biochemical features such as hyperferritinaemia, hypertriglyceridaemia and hypofibrinogenaemia are usually present, along with high levels of soluble interleukin 2 receptor in the blood and cerebrospinal fluid. Bone marrow aspirate may demonstrate the characteristic haemophagocytes, but initially is non-diagnostic in two-thirds of patients. Established international clinical, haematological and biochemical criteria now facilitate accurate clinical diagnosis. The disease is fatal unless a haematopoietic stem cell transplant (HSCT) is performed. The introduction of HSCT has dramatically improved the prognosis of the disease. However, the mortality of the disease is still significantly high and a number of challenges remain to be addressed. Active disease at the time of the transplant is the major significant poor prognostic factor. Delayed diagnosis, after irreversible organ damage has occurred, especially neurological damage, disease reoccurrence and pre-transplant mortality, remain a concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jordan, M. B., Hildeman, D., Kappler, J., & Marrack, P. (2004) · Blood · doi:10.1182/blood-2003-10-3413 · Cited by 712
Perforin-mediated target-cell death and immune homeostasis
Voskoboinik, I., Smyth, M. J., & Trapani, J. A. (2006) · Nature reviews. Immunology · doi:10.1038/nri1983 · Cited by 592
Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
Henter, J., Elinder, G., Soder, O., Hansson, M., Andersson, B., & Andersson, U. (1991) · Blood · doi:10.1182/blood.v78.11.2918.2918 · Cited by 505
The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis
Gupta, A., Tyrrell, P., Valani, R., Benseler, S., Weitzman, S., & Abdelhaleem, M. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21564 · Cited by 130 · cited 1×
“In patients with FHL there is accumulation of activated macrophages, lymphocytes and haemophagocytosis in the bone marrow, spleen, liver, lymph nodes and CNS. Hae-mophagocytosis may not be found in the initial stages of the disease [60,61].”
Cited by
Hemophagocytic lymphohistiocytosis: review of etiologies and management
George, M. (2014) · Journal of Blood Medicine · doi:10.2147/jbm.s46255 · Cited by 488
Hemophagocytic Lymphohistiocytosis: An Update on Diagnosis and Pathogenesis
Rosado, F. G. N., & Kim, A. S. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcp4zdkj4icouat · Cited by 338
Brisse, E., Wouters, C. H., & Matthys, P. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.10.001 · Cited by 204
“mediated apoptosis of target cells [3,7,8].”
BackgroundInfluential
Metadata
- Authors
- Gholam, C., Grigoriadou, S., Gilmour, K. C., & Gaspar, H. B.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-08
- Volume
- 163
- Issue
- 3
- Pages
- 271-283
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2135158821
- Cited by
- 168
- References
- 4
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.